Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DiaSorin Strikes Dx Partnership With MeMed To Address Antibiotic Overuse

Executive Summary

First licensing agreement for MeMed adds its immune system-based protein signature test to DiaSorin’s LIAISON test menu.

You may also be interested in...



MeMed Ready To Partner On IVD Technology That Can Cut Antibiotic Overuse

MeMed has received CE Marking for its diagnostic test MeMed BV and point-of-need platform MeMed Key, which uses the human immune system to distinguish between bacterial and viral infections to prevent antibiotic overuse.

Start-Up Spotlight: MeMed, Making Infectious Disease Dx Clearer With Immune Responsive Signatures

Israeli company MeMed has developed a proprietary diagnostic platform which uses proprietary immune system biomarkers to rapidly distinguish between viral and bacterial infections. The firm already has a CE -marked lab-based product, ImmunoXpert, which has been validated in three studies, the last of that trilogy having just published results confirming the test's ability to accurately distinguish between bacterial and viral infections.

Salvia Scores $31M To Develop Neurostimulation Therapy

The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.

Topics

Related Companies

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel